dromlakhani Add pharmacologic therapy to minimize hair regrowth after hair removal in known hyperandrogenemia
STEP 1 — Gather Information
Confirm documented hyperandrogenemia (elevated androgens, PCOS, NCCAH, or clinical hyperandrogenic signs) and record the hair removal method the patient is using or plans to use (laser, photoepilation, electrolysis, or other).
Action: Document hyperandrogenemia status and chosen hair removal modality.
STEP 2 — Rule In / Rule Out
Screen for contraindications to pharmacologic therapy: pregnancy without reliable contraception, active liver disease (for antiandrogens), uncontrolled hypertension, or high VTE risk without mitigation.
Decision: If no contraindications, proceed to Step 3; if contraindications exist, address them first or consider non‑pharmacologic optimization only.
STEP 4 — Decide
Prescribe oral combined estrogen–progestin contraceptive (low‑dose EE ≤ 20 mcg with low‑risk progestin per Table 2) as initial therapy; if the patient is not seeking pregnancy and desires additional antiandrogen effect, consider adding an antiandrogen (spironolactone 100–200 mg/day or finasteride 2.5–5 mg/day) after 6 months of OC monotherapy if regrowth persists.
Action: Initiate selected regimen and schedule follow‑up in 6 months to assess hair regrowth.
Clinical Guardrails / Mimics / Pitfalls
Do not use antiandrogen monotherapy without proven contraception due to teratogenic risk; avoid flutamide because of hepatotoxicity; do not rely on insulin‑lowering drugs (e.g., metformin) solely for hirsutism; monitor for VTE when using OCs in obese or >39‑year‑old patients; recognize that photoepilation may cause paradoxical hypertrichosis in Mediterranean/Middle Eastern women and adjust counseling accordingly.
Concrete Clinical Example
A 28‑year‑old woman with PCOS (Ferriman–Gallwey score 16, elevated free testosterone) undergoes facial laser hair removal but reports rapid regrowth within 4 weeks. She is not seeking pregnancy, has no liver disease, and uses barrier contraception. Start EE 20 mcg + norgestimate 0.25 mg daily. At 6‑month visit, regrowth is reduced but still bothersome; add spironolactone 100 mg twice daily. Regrowth markedly improves at the subsequent 6‑month assessment.
Source: Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-00241